1. Home
  2. ORMP vs ICUCW Comparison

ORMP vs ICUCW Comparison

Compare ORMP & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORMP
  • ICUCW
  • Stock Information
  • Founded
  • ORMP 2002
  • ICUCW N/A
  • Country
  • ORMP United States
  • ICUCW United States
  • Employees
  • ORMP N/A
  • ICUCW 19
  • Industry
  • ORMP Biotechnology: Pharmaceutical Preparations
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORMP Health Care
  • ICUCW Health Care
  • Exchange
  • ORMP Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • ORMP N/A
  • ICUCW N/A
  • IPO Year
  • ORMP N/A
  • ICUCW 2021
  • Fundamental
  • Price
  • ORMP $2.13
  • ICUCW $0.02
  • Analyst Decision
  • ORMP Hold
  • ICUCW
  • Analyst Count
  • ORMP 1
  • ICUCW 0
  • Target Price
  • ORMP N/A
  • ICUCW N/A
  • AVG Volume (30 Days)
  • ORMP 82.4K
  • ICUCW N/A
  • Earning Date
  • ORMP 08-15-2025
  • ICUCW N/A
  • Dividend Yield
  • ORMP N/A
  • ICUCW N/A
  • EPS Growth
  • ORMP N/A
  • ICUCW N/A
  • EPS
  • ORMP N/A
  • ICUCW N/A
  • Revenue
  • ORMP $2,000,000.00
  • ICUCW N/A
  • Revenue This Year
  • ORMP N/A
  • ICUCW N/A
  • Revenue Next Year
  • ORMP N/A
  • ICUCW N/A
  • P/E Ratio
  • ORMP N/A
  • ICUCW N/A
  • Revenue Growth
  • ORMP 196.74
  • ICUCW N/A
  • 52 Week Low
  • ORMP $1.82
  • ICUCW N/A
  • 52 Week High
  • ORMP $3.09
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • ORMP 42.92
  • ICUCW N/A
  • Support Level
  • ORMP $2.12
  • ICUCW N/A
  • Resistance Level
  • ORMP $2.20
  • ICUCW N/A
  • Average True Range (ATR)
  • ORMP 0.10
  • ICUCW 0.00
  • MACD
  • ORMP -0.01
  • ICUCW 0.00
  • Stochastic Oscillator
  • ORMP 29.55
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: